GSK hails progress for withdrawn blood cancer drug
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
Buy2h
GSK hails survival results in blood cancer patients with Blenrep
(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.
Daily4h
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
“Treatment options for myelofibrosis-related anemia have been limited. We are proud to offer this treatment alternative for ...
FiercePharma20h
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Pharmaceutical Technology21h
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...